TREM2 Antibody AL002: Early Alzheimer’s Phase 2 Trial
Alzheimer’s Drug AL002 Shows Promise, But Falls Short in Key Trial A new experimental treatment for early Alzheimer’s disease, the TREM2 agonistic antibody AL002, has demonstrated it can engage its target within the brain, offering a glimmer of hope in the fight against this devastating condition. However, a recently completed phase 2 clinical trial revealed … Read more